Technology | January 28, 2015| Dave Fornell

FDA Approves Transcatheter Pulmonary Valve

Medtronic Melody valve is granted wider market clearance over previous HDE designation

Melody valve, FDA approval, PMA, pulonary valve

The Melody valve being deployed in the pulmonary valve position.

Melody valve, FDA approval, PMA, pulonary valve

The U.S. Food and Drug Administration (FDA) has granted approval of Medtronic’s premarket approval application (PMA) for the Melody Transcatheter Pulmonary Valve (TPV) and its Ensemble Transcatheter Valve Delivery System. This allows wider use of the valve in patients born with congenital heart defects that often require multiple open-heart surgeries. The valve is designed to reduce the number of open surgeries and expand the time between them. 

 

The Melody was previously cleared under an FDA humanitarian device exemption (HDE) in January 2010. Under the HDE, the Melody became the first transcatheter valve approved for use in the United States, pre-dating the approval of the Edward’s Sapien.
 
The FDA said patients born with heart defects often receive a pulmonary valve conduit (an artificial graft with a valve inside that connects the heart to the lungs) to correct the defects. Over time, the conduit may become narrowed or leaky and will need to be replaced. The Melody TPV is used to treat a failing conduit.
 
Patients born with heart defects typically need several surgeries during their lifetime to correct their heart problems. The use of the Melody TPV will delay the time when a patient needs additional open-heart surgery. It can also reduce the total number of open-heart surgeries a patient needs.
 
The device is indicated for use as an adjunct to surgery in the management of pediatric and adult patients with the following clinical conditions:
• Existence of a full (circumferential) right ventricular outflow tract (RVOT) conduit that was equal to or greater than 16 mm in diameter when originally implanted; and
• Dysfunctional RVOT conduit with a clinical indication for intervention.
- more than moderate regurgitation and/or
- stenosis with a mean RVOT gradient of more than 35 mmHg
 
The Melody valve is made from the jugular vein valve of a cow that is sewn into a small metal frame. The Ensemble delivery system uses a balloon catheter to deploy the valve in the heart without open-heart surgery while the heart is beating. The device is first compressed onto the balloon at the tip of the delivery catheter for expansion in the native valve. The system uses femoral vein access. 
 
The FDA said patients who receive the device will be followed up to five years to study the long-term effects and safety of the device. The OSB PAS - Long-term follow-up study is a prospective, non-randomized, multi-center, historically controlled clinical trial, designed to assess the postmarket performance of the Melody TPV in a representative population of providers and patients, with 5-year follow-up. The primary endpoint is freedom from TPV dysfunction, with a performance goal of 75 percent or greater at six months. Secondary endpoints include procedural success, serious procedural- and device-related adverse events, stent fracture, re-intervention on the TPV, surgical replacement of the RVOT conduit, death (all-cause, procedure-related and device-related), and New York Heart Association (NYHA) classification.
 
For more information: www.accessdata.fda.gov/cdrh_docs/pdf14/P140017a.pdf
 
 

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Overlay Init